Top 10 Biotech Pipelines to Watch in 2026
Small to mid-sized biotechs ranked by the strength of their recently approved and late-stage assets.
The full biotech watchlist at a glance — assets, stage, peak sales and GTM stakeholder coverage.
This ranking looks at small to mid-sized biotechs with valuable recently approved and late-stage assets.
The key factors: pipeline depth, estimated peak sales and recent hiring activity across go-to-market stakeholders including commercial, marketing, medical affairs, market access, and patient services.
The 10 in detail
BridgeBio
Combined peak sales: ~$7.0B
The strongest portfolio on the list, with 4 valuable assets: Attruby, BBP-418, encaleret and infigratinib. Combined peak sales shown: ~$7.0B. Also notable: 135 mapped GTM stakeholders and 25 hires in the last 6 months.
Revolution Medicines
Combined peak sales: $7.6B
The clearest single-asset opportunity. Daraxonrasib is in Phase 3 for lung cancer / pancreatic cancer, with an estimated $7.6B peak sales opportunity. Hiring momentum is strong, with 40 GTM hires in the last 6 months.
Vertex
Combined peak sales: ~$14.6B
The largest company and combined opportunity on the list: ~$14.6B across Alyftrek, Journavx and povetacicept. Vertex has the highest GTM coverage and hiring activity, with 858 mapped GTM stakeholders and 53 hires in the last 6 months.
Insmed
Combined peak sales: ~$6.3B
A strong respiratory pipeline, with Brinsupri approved in bronchiectasis and Arikayce tied to a new indication in MAC. Combined peak sales shown: ~$6.3B. Also notable: 211 mapped GTM stakeholders and 20 recent hires.
Axsome
Combined peak sales: ~$9.25B
A high-value CNS portfolio, with Auvelity, AXS-12 and Symbravo representing around $9.25B in combined peak sales. Auvelity is the major driver, with an estimated $8.0B opportunity across depression / Alzheimer's agitation.
Ionis
Combined peak sales: ~$2.8B
A diversified rare disease / cardiometabolic pipeline, with Dawnzera, zilganersen and Tryngolza representing around $2.8B in combined peak sales. Ionis also has 169 mapped GTM stakeholders and 10 hires in the last 6 months.
Cytokinetics
Combined peak sales: $3.0B
A major cardiovascular launch opportunity. Myqorzo is approved in cardiomyopathy with an estimated $3.0B peak sales opportunity.
Cogent
Combined peak sales: $5.7B
A focused oncology opportunity. Bezuclastinib is at NDA stage in GIST / systemic mastocytosis with an estimated $5.7B peak sales opportunity. Cogent also shows a meaningful GTM hiring signal.
Sobi
Combined peak sales: ~$4.2B
A broad commercial and late-stage portfolio, with Gamifant, Tryngolza and SEL-212 representing around $4.2B in combined peak sales. Sobi also has 217 mapped GTM stakeholders and 14 hires in the last 6 months.
PTC Therapeutics
Combined peak sales: ~$1.86B
A rare disease pipeline with Kebilidi, Sephience and Vatiquinone across approved and Phase 3 stages. Combined peak sales shown: ~$1.86B, led by Sephience in PKU.
Honorable mentions
Viridian
Elegrobart and veligrotug are late-stage assets in thyroid eye disease, positioning Viridian as a potential competitor to Amgen's Tepezza.
Celcuity
Gedatolisib has submitted an NDA in breast cancer, with an estimated peak sales opportunity of ~$2.0B.
Scholar Rock
Apitegromab has submitted an NDA in SMA, with an estimated peak sales opportunity of ~$1.8B.
Interested in monthly pipeline news updates and the contacts working at these contacts and on these brands?